



## TalpherA to Report Second Quarter 2026 Financial Results on Wednesday, August 12, 2026

Aug 05, 2026

SAN MATEO, Calif., Aug. 5, 2026 /PRNewswire/ -- TalpherA, Inc. (Nasdaq: TLPH), ("TalpherA"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will host a conference call and webcast on Wednesday, August 12, 2026 at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss financial results for the second quarter ended June 30, 2026 and recent business progress.

### Conference Call and Webcast Information

- Date: Wednesday, August 12, 2026 at 4:30 PM ET/1:30 PM PT
- Participant Dial-in (North America): 1-800-836-8184
- Participant Dial-in (International): 1-646-357-8785
- Conference ID: 50873
- Webcast Access: Click [here](#)

The event can also be accessed in the Upcoming Events page in the Investors section of the TalpherA website at [www.talpherA.com](http://www.talpherA.com).

A replay of the webcast will be available on the TalpherA website for 90 days after the event.

### About TalpherA, Inc.

TalpherA, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. TalpherA's lead product candidate, Niyad<sup>®</sup> is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Nafamostat has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA).

This release is intended for investors only. For additional information about TalpherA, please visit [www.talpherA.com](http://www.talpherA.com).



 View original content to download multimedia: <https://www.prnewswire.com/news-releases/talpherA-to-report-second-quarter-2026-financial-results-on-wednesday-august-12-2026-302844071.html>

SOURCE TalpherA, Inc.

Investor Contacts, TalpherA, Raffi Asadorian, CFO, 650-216-3500, [investors@talpherA.com](mailto:investors@talpherA.com); LifeSci Advisors, Kevin Gardner, 617-283-2856, [kgardner@lifesciadvisors.com](mailto:kgardner@lifesciadvisors.com)